Bouralexis S - Search Results

1

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.

Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai le M, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A. Butler LM, et al. Among authors: bouralexis s. Int J Cancer. 2006 Aug 15;119(4):944-54. doi: 10.1002/ijc.21939. Int J Cancer. 2006. PMID: 16550602

2

Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.

Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM. Evdokiou A, et al. Among authors: bouralexis s. Int J Cancer. 2002 Jun 1;99(4):491-504. doi: 10.1002/ijc.10376. Int J Cancer. 2002. PMID: 11992538

3

Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro.

Nakamura A, Ly C, Cipetić M, Sims NA, Vieusseux J, Kartsogiannis V, Bouralexis S, Saleh H, Zhou H, Price JT, Martin TJ, Ng KW, Gillespie MT, Quinn JM. Nakamura A, et al. Among authors: bouralexis s. Bone. 2007 Feb;40(2):305-15. doi: 10.1016/j.bone.2006.09.001. Epub 2006 Oct 13. Bone. 2007. PMID: 17049328

4

IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice.

Quinn JM, Sims NA, Saleh H, Mirosa D, Thompson K, Bouralexis S, Walker EC, Martin TJ, Gillespie MT. Quinn JM, et al. Among authors: bouralexis s. J Immunol. 2008 Oct 15;181(8):5720-9. doi: 10.4049/jimmunol.181.8.5720. J Immunol. 2008. PMID: 18832731

5

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

Cheung V, Bouralexis S, Gillespie MT. Cheung V, et al. Among authors: bouralexis s. PLoS One. 2013 Jun 18;8(6):e66343. doi: 10.1371/journal.pone.0066343. Print 2013. PLoS One. 2013. PMID: 23822995 Free PMC article.

6

Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.

Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M. Zopf S, et al. Among authors: bouralexis s. Int J Oncol. 2007 Dec;31(6):1391-402. Int J Oncol. 2007. PMID: 17982666

7

Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.

Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A. Thai le M, et al. Among authors: bouralexis s. Cancer Res. 2006 May 15;66(10):5363-70. doi: 10.1158/0008-5472.CAN-05-4386. Cancer Res. 2006. PMID: 16707463

8

Death to the bad guys: targeting cancer via Apo2L/TRAIL.

Bouralexis S, Findlay DM, Evdokiou A. Bouralexis S, et al. Apoptosis. 2005 Jan;10(1):35-51. doi: 10.1007/s10495-005-6060-0. Apoptosis. 2005. PMID: 15711921 Review.

9

Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin.

Bouralexis S, Clayer M, Atkins GJ, Labrinidis A, Hay S, Graves S, Findlay DM, Evdokiou A. Bouralexis S, et al. Int J Oncol. 2004 May;24(5):1263-70. doi: 10.3892/ijo.24.5.1263. Int J Oncol. 2004. PMID: 15067350

10

Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.

Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Evdokiou A, et al. Among authors: bouralexis s. Bone. 2003 Aug;33(2):216-28. doi: 10.1016/s8756-3282(03)00223-0. Bone. 2003. PMID: 14499355

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters